Immunopharm Flashcards Preview

PHARM 2 > Immunopharm > Flashcards

Flashcards in Immunopharm Deck (60):
1

glucocorticoids AE: short/long term

short term: HTN, hyperglycemia, psychosis, cognitive impairment

long term: myopathy, Cushing syndrome, osteoporosis

2

cyclosporine

calcineurin inhibitor

3

tacrolimus

calcineurin inhibitor

4

cyclosporine AE

*nephrotoxicity
tremor
hyperglycemia/hyperlipidemia
osteoporosis
*hirsutism
*gum hyperplasia

5

Cyclosporine interactions

CYP3A4 metabolizer

6

cyclosporine uses

organ transplant, uveitis, RA, psoriasis

7

tacrolimus AE

same as cyclosporine: nephrotoxicity, hyperglycemia/lipidema, hyperkalemia AND neuro sxs!!

8

tacrolimus use

prevent rejection of transplanted kidneys, liver, heart

topical for atopic dermatitis and psoriasis

9

sirolimus AE

myelosuppresion
hepatotoxicity
hyper TG
pneumonitis

10

sirolimus

proliferation signal inhibitors
binds FKBP - inhibits mTOr kianse = block T cell proliferation

mTOR blocks IL-2 driven T cell proliferation: Th1

11

thalidomide

angiogenesis inhibitor and TNF-alpha inhibitor

12

thalidomide use

erythema nodosum leprosum and MM

13

lefluonomide

anti-metabolite - cytotoxic agent

14

mycophenolate mofetil

anti-metabolite - cytotoxic agent
inhibits inosine monophoshpate dehydrogenase

15

methotrexate

anti-metabolite - cytotoxic agent

16

azathioprine

anti-metabolite - cytotoxic agent

17

azathioprine AE

BM suppression, GI disturbances, inc in infections

18

azathioprine warning

if taken with allopurinol, dec dose of azathioprine

19

azathioprine use

prevent organ transplant rejection

severe RA

20

MTX AE

mucosal ulcers
luekopenia
anemia
hepatotoxicity

can be reduced with leucovorin or folic acid
contraindic in pregnancy

21

MTX uses

RA
psoriasis
ankylosing spondylitis
SLE

22

mycophenolate mofetil AE

n/v/d
HA
HTN
reversible myelosuppresion

23

mycophenolate mofetil uses

prophylaxis of transplant rejection
SLE

24

leflunamide AE

reversible alopecia
myelosuppresion
INC aminotransferase activity
monitor CBC and LFTs
carcinogenic and teratogenic in animals
diarrhea

contraindicated in pregnancy

25

leflunomide use

RA, SLE, MG

26

cyclophosphamide

alkylating agent

27

cyclophosphamide AE

BM suppression
hemorrhagic cystitis
bladder carcinoma
acrolein = urine toxin
infertility

28

hydroxychloroquine AE

hemolysis in G6PD def
retinal damage

29

sulfasalazine AE

neutropenia
thrombocytopenia
drug induced Lupus
hemolysis in G6PD
n/v

30

sulfasalazine use

UC
RA
CD
ankylosing spondylitis

31

rituximab

anti-CD20 - depletes B cells

nonhodgkins lymphoma, CLL, RA

32

basiliximab

IL-2 antagonist

33

omalizumab

anti-IgE antibody

34

etanercept

TNF-alpha binding

35

adalimumab

anti-TNF alpha
human IgG1

36

infliximab

anti-TNF alpha
chimeric monoclonal antibody

37

anakinra

IL-1 blocker

38

leflunoamide MOA

inhibits dihydroorate dehydrogenase

39

MTX MOA

inhibit AICAR transformylase (aminoimidazolecarboxamide ribonucleotide transformylase)

responsible for catalyzing final steps of purine synthesis and IMP synthesis

40

aldesleukin

recombinant IL-2
promotes production of cytotoxic T cells and activation NK

41

aldesleukin use

adjuvant for renal cell CA and malignant melanoma

42

IFN-alpha use

hairy cell leukemia
MCL
malignant melanoma
Kaposi sarcoma
HBV, HCV

43

IFN-beta use

relapsing MS

44

IFN-gamma use

treat CGD

45

bacillus calmette geurin

tx and prophylaxis bladder ca

46

BCG AE

hypersensitivity
shock
immune complex disease

47

glucorticoids on PLA-2 and COX-2

Inhibit PLA-2
Reduce transcription of COX-2

48

calcineurin mechanism

phosphatase necessary for activation of T cell specific transcription factor: NFAT

49

cyclosporine MOA

complexes with cyclophilin - immunophillin = this complex inhibits calcineurin

50

tacrolimus MOA

binds FK binding protein = immunophilin - inhibits calcineurin

51

tx for erythema nodosum leprosum

thalidomide

52

tx for multiple myeloma

thalidomide

53

azathioprine MOA

converts to 6-MP: inhibit de novo purine synthesis
suppresses B and T cell function, dec IL-2 secretion

54

what accumulates with use of MTX

AMP
(converted extracellularly to adenosine - potent inflam inhibitor)

55

mycophenolate mofetil MOA

converted to mycophenolic acid: inhibits IMP dehydrogenase in de novo pathway of GTP synthesis

suppresses B and T activation

56

leflunomide

prodrug - terfluonmide
inhibits Dihydroorotate dehydrogenase

Increases UMP - needed for pyrimidine synthesis

57

what lab values should be checked in people leflunomide

CBC
LFTs

58

cyclophosphamide MOA

alkylates DNA = destroys proliferating lymphoid cells

59

tx of UC

sulfasalazine -- the 5-ASA moiety

60

abatacept

fusion protein - interferes with T cell activation